Sponsored by:
WuXi XDC Research Platform & Capability for Integrated Bioconjugation Discovery Services
WuXi XDC has established a one-stop discovery service platform, covering from protein/antibody generation, linker-payload synthesis, bioconjugation, in vitro/in vivo functional studies and developability study, for bioconjugate drugs to meet the early research needs of the customers.
Since the year of 2000, there’re 13 ADCs on the market and 9 of them were approved in the last three years. The enthusiasm of pharmaceutical and biotechnology companies for the research and development of ADC has been increasing. How to quickly complete the early development of ADC through differentiation strategy has become an important link for companies to focus on competition. WuXi XDC has established a one-stop discovery service platform, covering from protein/antibody generation, linker-payload synthesis, bioconjugation, in vitro/in vivo functional studies and developability study, for bioconjugate drugs to meet the early research needs of the customers.
Audience
-
Scientists
-
Bioprocess Engineers
-
Bioproduction Engineers
-
Process Development Engineers
-
Process Development Managers
-
Consultants R&D Scientists
